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ABSTRACT 
 
URINARY MELATONIN LEVELS AND RISK OF POSTMENOPAUSAL BREAST 
CANCER IN THE WOMEN’S HEALTH INITIATIVE OBSERVATIONAL STUDY  
 
MAY 2012 
 
ASHLEY DOHERTY, B.A, UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S, UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Dr. Susan R. Sturgeon 
 
 Prior studies have observed a link between night shift work and increased risk of 
breast cancer. Melatonin, a hormone related to circadian rhythm, has been proposed to 
lower breast cancer risk by inhibiting cell proliferation. The disruption of peak melatonin 
that occurs during night shift work could explain the increase in risk observed. Several 
studies have assessed whether higher melatonin levels are associated with decreased 
breast cancer risk, but results have been conflicting. We examined the relationship 
between urinary melatonin levels and breast cancer risk in a nested case-control study 
conducted within the Women’s Health Initiative Observational Study. First morning 
urine samples collected at baseline were assayed for melatonin levels in 258 women 
diagnosed with invasive breast cancer and 515 matched controls from three enrollment 
sites. Using conditional logistic regression to adjust for matching factors and established 
 iv 
risk factors, results indicate no association between urinary melatonin levels and breast 
cancer risk. The mean creatinine adjusted melatonin levels for cases and controls were 
16.30 ng/mg and 16.05 ng/mg, respectively. Compared to the lowest quartile of creatinine 
adjusted melatonin, the odds of breast cancer did not vary by quartile of creatinine 
adjusted melatonin, adjusted for known breast cancer risk factors: second quartile 0.84 
(95% CI 0.52-1.38), third quartile 1.05 (95% CI 0.65-1.72) and fourth quartile 1.09 (95% 
CI 0.66-1.81). This study does not suggest that melatonin is protective against breast 
cancer and suggests that reasons other than melatonin suppression may explain the 
increased risk of breast cancer seen in night shift workers.  
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CHAPTER I 
INTRODUCTION 
 The American Cancer Society has estimated that 226,870 women will be 
diagnosed with breast cancer and 39,510 women will die of breast cancer in 2012 in the 
United States.1 On January 1, 2008, 2,632,005 U.S women had a history of breast cancer. 
From 2003 to 2007, the annual age-adjusted death rate in the United States for breast 
cancer was 24 per 100,000 women per year.2 The median age of death for breast cancer 
was 68 years old.2 A vast majority of breast cancers occur in postmenopausal women, 
with an estimated 78.2% of breast cancer diagnoses in women over the age of 55 from 
2003-2007.2  
 Previous literature has found a link between night shift work and breast cancer.4, 5 
Interruption of melatonin production caused by night shift work may explain the increase 
in breast cancer risk.5,6 Melatonin is a hormone found in the pineal gland that circulates 
throughout the body and influences circadian rhythm. Melatonin may affect breast cancer 
risk by decreasing cell proliferation and limiting tumor growth. Current epidemiological 
literature points towards a relationship between melatonin levels and breast cancer risk. A 
majority of prospective studies have found an inverse association between urinary 
melatonin levels and breast cancer risk7-11, though not all results have been statistically 
significant.7-9,12 Prospective studies focusing on postmenopausal women using the more 
reliable first morning urine samples will aid this growing field of research. Therefore, we 
conducted a nested case-control study within the Women’s Health Initiative 
Observational Study to assess urinary melatonin, as measured through first morning 
urine, and subsequent postmenopausal breast cancer risk.  
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CHAPTER II 
REVIEW OF THE LITERATURE 
Shift work and Breast Cancer Risk 
 In 2010, the International Agency for Research on Cancer (IARC) published a 
report that concluded shift work that disrupts circadian rhythm is probably carcinogenic 
to humans.5 The IARC assesses a variety of data sources, including studies conducted in 
human and animals. There was limited evidence in humans for this relationship and 
sufficient evidence from experiments conducted with animals. The variety of definitions 
of shift work is one difficulty in assessing the relationship between cancer and shift work. 
In general, shift work is defined as working irregular hours, typically outside the standard 
daylight hours of 8 am to 6 pm.  In the United States, shift workers make up 
approximately 15% of the fulltime work force work.5  
 A total of eight studies have looked specifically at shift work and breast cancer 
risk. A meta-analysis analyzing six of these eight studies was conducted by Megdal et al. 
(2005).13 The authors found a 51% increased risk of breast cancer in these studies among 
night shift workers excluding airline cabin crew, including both pre- and postmenopausal 
breast cancer (RR 1.51, 95% CI 1.36-1.68). A majority of women included in these 
studies were postmenopausal. Airline cabin crew were excluded from this analysis, but 
when included the results were similar (RR=1.48, 95% CI 1.36-1.61). A limitation of this 
meta-analysis is that each study used varying definitions of shift work, which limits the 
comparability of the studies.5 Due to the fact that shift work disrupts circadian rhythm 
and peak melatonin production, the hormone melatonin is often cited as a potential 
biological mechanism for the association between shift work and breast cancer. 
 3 
 
Biological Mechanisms of Melatonin and Breast Cancer Risk  
 Melatonin is a hormone that influences circadian rhythms in bacteria, plants and a 
variety of vertebrates, including humans.5 As light enter the eyes, the information is 
processed by the hypothalamus sending a signal to the pineal gland, which secretes 
melatonin. The peak melatonin secretion occurs during the night, between 2-3 am, but 
can be suppressed by light.5,6 In experimental studies, it has been found that animals that 
are either exposed to light during typical dark periods or who have received a 
pinealectomy, the removal of the pineal gland, can experience disruption in the timing 
and the duration of melatonin secretion.5 A growing body of literature suggests that night 
shift work is related to breast cancer risk through nighttime light exposure, and perhaps 
lower melatonin levels. There has been some conflicting evidence in this regard, as a 
recent study conducted within Canadian nurses by Grundy et al. (2011) has found no 
association between night shift light exposure and melatonin levels.14  No significant 
decrease in melatonin levels was found between female nurses working the night shift 
and those working the day shift on a rapidly rotating shift schedule. The authors did 
address the fact that light exposure experienced by the nurses within the study, 37.2 lux, 
was well below the level found to decrease melatonin levels in experimental studies, 200 
lux. The effects of melatonin on breast cancer are only recently beginning to be 
understood, but it is hypothesized that melatonin is able to effect breast cancer risk 
through suppression of cell growth and proliferation.5,6  
 Studies have shown that melatonin is able to suppress the proliferation of both 
estrogen receptor alpha-positive and estrogen receptor negative human breast cancer cells 
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in vitro.6 A linear dose response relationship has been observed between melatonin and 
suppression of these cells, indicating that higher levels of melatonin is associated with 
increased cancer cell suppression.6 Melatonin is able to block estrogen receptors, thus 
decreasing the likelihood that the breast cancer will be able to form.  
 The anti-proliferative effect of melatonin is believed to occur through at least four 
pathways.5 First, the prevention of the uptake of linoleic acid has been shown to have an 
inhibitory effect, preventing the growth of tumor cells.5,15  Linoleic acid is thought to be 
an energy source for tumor growth, so inhibition of linoleic acid by melatonin would 
prevent excess cell growth.15 Second, in experimental studies done in vitro, melatonin has 
been shown to inhibit the mitogenic action of hormones and growth factors, e.g. estradiol 
and prolactin. This again prevents the growth of cancerous cells. Third, melatonin 
increases the expression of the tumor suppressor gene TP53. Finally, melatonin down 
regulates aromatase expression. This down regulation diminishes the rate of tumor 
growth and proliferation.5   
 Overall, melatonin has been found to suppress cell proliferation. This inhibition of 
cell proliferation, through the blockage of estrogen and linoleic acid receptors, inhibition 
of growth factors and hormones, increase of TP53 and down regulation of aromatase, is 
the mechanism through which higher levels of melatonin might protect women against 
breast cancer.5,6,15 
Epidemiology of Melatonin and Breast Cancer Risk 
 Relatively few studies have examined the relationship between urinary melatonin 
levels and breast cancer risk.7-12 Five prior studies were nested case-control studies in 
which the cases and controls came from large prospective cohort studies 8-12 and one was 
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a retrospective case-control study.7 The following are the three studies which included 
information on postmenopausal breast cancer.9,10,12 
 In the first prospective study to consider the association of urinary melatonin 
levels and breast cancer risk, Travis et al. conducted a matched nested case-control study 
of 127 cases and 353 controls participating in the Guernsey Cohort, a prospective cohort 
study of 5,093 women living on the island of Guernsey in the British Isles from 1977 to 
1985.12 This is the only study to use the 24-hour method of urine collection. Women 
answered a baseline questionnaire that included information on reproductive history, 
menopausal status, past use of oral contraceptives and other hormones and breast cancer 
screening history. After recruitment, women were asked to provide a 24-hour urine 
sample. Breast cancer cases were obtained through the Wessex Cancer Registry, death 
certificates, and pathology reports through October 31, 2001. Each case was matched to 
three controls on the basis of age, date of recruitment and menopausal status.  
 Urine samples were thawed and assayed by radioimmunoassay with 125I-labeled 
tracer in 2002. Among postmenopausal women only, relative to the women in the first 
tertile, those in the second tertile of creatinine adjusted melatonin had 24% lower risk of 
breast cancer (OR = 0.76, 95% CI 0.31-1.84) and women in the third tertile of melatonin 
had 1.09 times the risk of breast cancer compared to those in the lowest tertile of 
creatinine adjusted melatonin (OR=1.09, 95% CI 0.46-2.6).  When restricted to only 
women with invasive breast cancer, the results did not change significantly. Although 
there was a wide confidence interval, this study suggests there is no association between 
melatonin and breast cancer risk. This study, however, may be subject to nondifferential 
misclassification of the exposure, as the 24-hour sample method has not been found to be 
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reliable for measuring peak melatonin levels that occur during the night.4,7  The study also 
had a small sample size, limiting its power to find a modest association between 
creatinine adjusted melatonin levels and breast cancer risk. 
 In the largest study to date, using first morning urine collection, Schernhammer et 
al. conducted a nested case-control study of 357 cases and 533 matched controls to 
evaluate the relationship between creatinine adjusted urinary melatonin and breast cancer 
risk in the Nurses’ Health Study, a prospective cohort that began in 1976, following 
121,700 registered nurses ages 30 to 55 in the United States.10 At baseline, eligible nurses 
completed a questionnaire about their health status, medical history and known or 
suspected risk factors for cancer and heart disease. These questionnaires were 
administered every two years to identify new risk factors and diagnosis of disease. In 
December 2002, 18,706 women provided a blood sample as well as a first morning urine 
sample. Time of menstrual cycle was not recorded, as most of the cohort was 
postmenopausal at the time of collection. Cases were defined as women who were not 
diagnosed with any cancer, except for non-melanoma skin cancer, prior to urine 
collection and were diagnosed with breast cancer during follow-up through May 31, 
2006. Two controls were matched for each case on year of birth, menopausal status, 
recent postmenopausal hormone use, month and time of day of urine collection and 
fasting status at urine draw. The exceptions were postmenopausal breast cancer cases 
with hormone use who were matched with only 1 control.  
 Relative to women in the lowest quartile of creatinine adjusted melatonin, women 
in the second quartile had 1.17 times the risk of invasive breast cancer (OR 1.17, 95% CI 
0.75-1.82), women in the third quartile had a 30% lower risk of invasive breast cancer 
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(OR=0.70, 95% CI 0.43-1.12) and women in the fourth quartile of melatonin had a 26% 
lower risk of invasive breast cancer (OR=0.74, 95% CI 0.46-1.21),  (ptrend = 0.03). The 
associations seen between in situ breast cancer and creatinine adjusted melatonin, though 
based on small numbers, were stronger than those seen for invasive breast cancer, with 
women in the highest quartile at 77% lower risk of in-situ breast cancer compared to 
those in the lowest quartile (OR=0.23, 95% CI 0.08-0.69). There were no significant 
differences in the results when restricted to women with ER+ receptor status. One 
limitation of the study is the relatively short follow-up time. Urine collection occurred in 
2002 and all cases were diagnosed by 2006, with an average follow-up time of 2.5 years 
for the cases. Restricting analysis to those women who were diagnosed after 2 years did 
not significantly alter the results.  The short follow-up time could mean that melatonin 
levels were already being affected by undiagnosed breast cancer. 
 The first nested case-control study to look at only postmenopausal breast cancer 
was conducted by Schernhammer at al. among 178 cases and 710 controls within the 
ORDET cohort, an Italian study that recruited women from 1987 through 1992.9 At 
baseline, women completed a questionnaire of health characteristics, as well as provided 
a blood and urine sample. Each case was matched with 4 controls that were free of cancer 
at the time of the diagnosis for the case, matching on age at enrollment, date of 
recruitment and laboratory batch. Urine collection was completed through a twelve-hour 
overnight collection.  Relative to women in the first quartile of melatonin levels, women 
in the second quartile of melatonin levels had a 30% lower risk of invasive breast cancer 
(OR=0.70, 85% CI 0.43-1.14), women in the third quartile of melatonin levels had 18% 
lower risk of invasive breast cancer (OR=0.82, 95% CI 0.50-1.34) and women in the 
 8 
fourth quartile of melatonin levels had a 41% lower risk for invasive breast cancer 
(OR=0.59. 95% CI 0.35-1.00), (ptrend = 0.04). This study did not include any information 
on sleep disturbance or night shift work, which could have been an important factor to 
include in the analysis. A subanalysis was conducted using creatinine adjusted melatonin 
levels, which did not significantly change the results. Inclusion of the 7 cases of in situ 
breast cancer also did not change the results. Removal of current smokers strengthened 
the results, while restriction to current smokers caused an increase in risk when 
comparing the highest tertile of melatonin to the lowest (OR=3.55, 95% CI 0.61-20.8). 
The results were limited due to small number of current smokers. Exclusion of those 
diagnosed within 2 years and 4 years of urine collection strengthened the results (highest 
versus lowest quartile of melatonin OR=0.35, 95% CI 0.17-0.71, OR=0.34, 95% CI 0.15-
0.75, respectively).  
 Overall, the literature is conflicting on the association between urinary melatonin 
levels and breast cancer risk. Conflicting results may be due to poor assessment of 
urinary melatonin, such as through 24-hour samples as opposed to the more reliable first 
morning sample. Nested case-control studies that used the overnight and first morning 
urinary analysis9-11 found a non-significant inverse relationship between urinary 
melatonin and breast cancer risk, while those studies using 24-hour samples found no 
association between creatinine adjusted melatonin and breast cancer risk.8 Additionally, 
retrospective case-control studies are unable to assess urinary melatonin until after the 
diagnosis of breast cancer, which could have altered melatonin level and may explain the 
lack of significant results in this study design.7  One study has limited follow-up and 
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could potentially be finding the effect of undiagnosed breast cancer altering melatonin 
levels.10  
Summary 
 The Surveillance Epidemiology and End Results (SEER) program of the National 
Cancer Institute estimates that 1 out of 8 woman born today will be diagnosed with breast 
cancer in their lifetime.2 With increased amount of light exposure and sleep disruption, 
through night shift work or otherwise, there is a possibility that melatonin levels could be 
suppressed and potentially lead to an increased risk of breast cancer via less inhibition of 
breast cancer cells and their receptors.6 Current studies lack lengthy follow-up periods 
and adequate collection of urine samples from women prior to their diagnosis of breast 
cancer. More prospective research needs to be conducted in order to assess the 
relationship between melatonin and breast cancer.   
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CHAPTER III 
METHODS 
Study Aims and Hypothesis 
 
 Specific Aim: We evaluated the association between urinary levels of melatonin 
and risk of postmenopausal invasive breast cancer through a nested case-control study 
among participants from the Women’s Health Initiative Observational Study. 
 Hypothesis: There is an inverse association between urinary melatonin levels and 
risk of postmenopausal invasive breast cancer.  
Study Design and Population 
 
 To examine the association between urinary melatonin levels and risk of breast 
cancer, we conducted a nested case-control study within the Observational Study (OS) 
arm of the Women’s Health Initiative (WHI) among total of 258 cases of invasive 
postmenopausal breast cancer and 515 matched control subjects.  
 The OS recruited women from September 1993 to December 1998, enrolling a 
total of 93,676 women who were followed for eight to twelve years. Eligible women 
were between the ages of 50-79 years old, postmenopausal at enrollment (no menstrual 
cycles for at least twelve months prior to enrollment if 54 years old or younger and six 
months if 55 years old or older) with the intention to reside in the area for at least 3 years 
after enrollment. Exclusion criteria included any medical condition that had a predicted 
survival rate of less than 3 years, as well as any conditions that may have limited the 
ability to comply or stay within the study, such as alcohol or drug dependency, mental 
illness, dementia or active participation in another randomized control trial.3  Both cases 
and controls also had the following exclusion criteria: self-reported history of any cancer 
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prior to WHI enrollment (other than non-melanoma skin cancer), self-report and/or 
adjudicated cancer during WHI follow-up (other than non-melanoma skin cancer or 
breast cancer for cases) and inadequate urine from screening visit 1. 
Exposure Assessment 
 
 The exposure of interest is first morning urinary melatonin. Women who enrolled 
in the OS provided a first morning urine sample at one of three bone density sites 
(Birmingham, Pittsburgh and Tucson) at screening visit 1. When the liver metabolizes 
melatonin, it becomes the metabolite 6-sulfatoxymelatonin (aMT6s) found in the urine. 
Urinary melatonin level, aMT6s, was assessed through competitive enzyme-linked 
immunosorbent immunoassay (ELISA) and adjusted for creatinine levels to control for 
urine volume. The aMT6s levels were assessed as both a continuous and ordinal variable, 
divided into quartiles based upon levels within the controls. 
Validity of Exposure Assessment 
 
 ELISA has been shown to be reliable for measuring aMT6s levels, with intra-
assay and interassay correlation coefficients of 7.1 and 11.9% respectively, meaning that 
there is little variation between and within samples, thus small chances for laboratory 
errors.16 Baskett et al. found that urinary melatonin levels were correlated with plasma 
melatonin levels in elderly populations (R2 = 0.797).17  Urinary melatonin can be used to 
measure peak melatonin levels, as opposed to having to use a more invasive nighttime 
blood draw.17 Additionally, this metabolite has been found to be highly correlated with 
peak overnight melatonin levels when measured as a first morning urine void.18,19 Data 
from the Nurses’ Health Study also found an intra-class correlation coefficient of 0.72 for 
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first morning urine void over a three-year period, indicating that melatonin levels are 
relatively stable over time.4 
Outcome Assessment 
 
 Cases and controls were individually matched on enrollment date, age at 
enrollment and randomization clinic, with a ratio of 1:2 cases to controls. Cases are 
women who had adjudicated diagnosis of invasive breast cancer at one of three 
enrollment sites during their WHI follow-up (Birmingham, Pittsburgh and Tucson). 
Cases reported their breast cancer diagnosis through the annual questionnaire. Those who 
reported a breast cancer diagnosis had their medical records reviewed to adjudicate the 
diagnosis.20 Controls were women from these enrollment sites without a breast cancer 
diagnosis (invasive or non-invasive) during their WHI follow-up. 
Validity of Outcome Assessment 
 
 The baseline questionnaire for enrollment into the WHI has very high reliability, 
with a reliability coefficient of 0.89 for reporting of a history of breast cancer.13 
Additionally, self-report of breast cancer has been found to be a reliable measure of 
breast cancer rates in observational studies.22-24 
Covariate Assessment 
 
 Data on demographics, physical characteristics, behavioral characteristics, 
medication use and additional variables believed to be associated with breast cancer were 
collected through standardized questionnaires administered at baseline and updated over 
the course of followup.21 The variables of interest for this study include age, ethnicity, 
education level, height, weight, body mass index, hormone use, history of breast biopsy 
and benign breast disease, age at menarche, age at menopause, type of menopause 
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(natural, hysterectomy, bilateral oophorectomy), age at first child’s birth, number of 
pregnancies, breast feeding, marital status, prior needle aspiration of a breast lump, oral 
contraceptive use, current medication, first degree relative with breast cancer, energy 
expenditure from physical activity (MET hr/wk), sleep quality, alcohol intake and 
smoking status. 
Statistical Analysis  
 Upon inspection of the data, it was found that one case had missing melatonin 
levels and one control had a melatonin level that was an obvious outlier (1971.28 ng/mg). 
These participants were removed from analysis, along with their matched pairs. This left 
773 observations for analysis, 258 cases and 515 matched controls. We used t-tests and 
chi square tests as appropriate to test if there was a difference in the covariates of interest 
in cases and controls. A t-test was also conducted to see if there was a difference between 
mean melatonin levels in cases and controls (Table 1). Those categorical variables with 
small cell counts were collapsed. The distribution of continuous melatonin levels, 
adjusted for creatinine, was assessed for normality using the Shapiro-Wilk test. Due to 
the non-normal distribution of melatonin, Kruskal-Wallis tests were used to test whether 
the median creatinine adjusted melatonin levels in controls differed by covariates (Table 
2).  
 As this was a matched study design, we used conditional logistic regression to 
determine if higher levels of creatinine adjusted urinary melatonin is associated with 
lower odds of invasive breast cancer. We divided creatinine adjusted melatonin levels 
into quartiles based on control levels, using the lowest level of melatonin as the referent 
group.  
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 To address potential confounding, we included covariates identified in previous 
studies as known risk factors for breast cancer established within WHI25, as well as 
covariates included in other studies assessing the relationship between melatonin and 
breast cancer risk. Due to small numbers, ethnicities collapsed into white, black or other 
race. Highest education levels were collapsed into high school or less, college, post 
graduate or missing. Marital status was collapsed into never married, divorced/separated, 
widowed, married or marriage like relationship, or missing. Age at menarche was 
collapsed into 11 or less, 12-13 years, 14-15, 16 or older or missing. Hours of sleep was 
collapsed into 5 or less hours, 6 hours, 7 hours, 8 hours, 9 or more hours, or missing. 
Estrogen and progesterone duration was collapsed into none, less than 5 years, 5 to less 
than 10 years, 10+ years or missing.  Body mass index was collapsed into less than or 
equal to 24.9, 25-29.9, 30-34.9, or 35+. Quality of sleep was collapsed into restless, 
average quality, or restful.  Hysterectomy, needle aspiration, bilateral oophorectomy were 
included as ever/never. Oral contraceptive use and female relative with breast cancer 
were included as yes/ no. Smoking status was included as never, past or current smoker.  
Number of live births was included as never pregnant, never had term pregnancy, 1, 2-4, 
or 5+ pregnancies. Age at first birth was included as never pregnant, less than 20 years, 
20-29 years, 30+ years or missing. Alcohol intake, total energy expenditure and age of 
menopause were continuous variables. Age and region were controlled for by their use as 
matching factors.  
 Regression analyses began with the fitting of single predictor conditional 
regression models for each variable with the outcome of invasive breast cancer (Table 1). 
These results were used to assess the predictive significance of WHI breast cancer risk 
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factors and established risk factors used in other studies. An initial multiple predictor 
conditional logistic regression model was fit controlling for matching factors (enrollment 
date, age at enrollment and enrollment site) with the following predictors: ethnicity, age 
of menopause, needle aspiration of the breast, energy expenditure from recreational 
activities, duration of estrogen and progesterone use, time since quitting hormone 
replacement therapy, body mass index and highest education level. Adjusted odds ratios 
were calculated using the lowest creatinine adjusted melatonin quartile as the referent 
group (Table 3). Predictors in this initial multiple predictor conditional logistic regression 
model was retained for inclusion in subsequent models if its associated likelihood ratio 
test was statistically significant at p <0.10. Another multiple predictor conditional logistic 
regression model was fit using creatinine adjusted melatonin as a continuous variable. 
 We conducted sensitivity analysis by removing current smokers from our analysis 
as a previous study had found an effect by smoking status.9 We also estimated a model in 
which we restricted our analysis to only those with ER+ receptor status to see if there was 
any difference in this population as previous studies had looked at this population (Table 
4). 9,10   
 To assess the potential for a disease effect of undiagnosed breast cancer, another 
model was fit restricting the population into those diagnosed before and after 4 years 
from urine collection. Then, we divided the population into those diagnosed from 4-7 
years and those diagnosed after 7 years (Table 5).  
 Finally, while previous studies have not found a significant relationship between 
sleep duration and melatonin levels10, we constructed a model with sleep duration and 
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breast cancer risk, to see if there was any association (Table 6). All statistical analysis 
was conducted using Stata V. 12.1.  
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CHAPTER IV 
RESULTS  
 Mean creatinine adjusted melatonin levels were 16.29 ng/mg (sd=11.9) for cases 
and 16.05 ng/mg (sd=12.9) for controls. Characteristics of cases and controls are shown 
in Table 1 along with crude odds ratios from single predictor conditional logistic 
regression. At baseline, cases and controls differed in a few characteristics.  
 Contrary to what is typically seen in breast cancer studies, women who had a later 
age at first birth were at a lower risk of breast cancer relative to women who had their 
birth at less than 20 years of age. The risk of breast cancer was 26% lower for women 
who gave birth at 20-29 years old (95% CI 0.47-1.18), 42% lower for women who gave 
birth at 30 or older (0.28-1.21) and there was no association for women who never gave 
birth (OR=0.99, 95% CI 0.56-1.75) relative to women who had their first birth at less 
than 20 years old. All other known breast cancer risk factors indicated the correct 
direction of risk for breast cancer.  With each one-point increase in body mass index there 
was a 1.12 times increased risk of breast cancer (95% CI 0.96-1.30). For each one-year 
increase in age of menopause, there was 1.02 times increased risk of breast cancer (0.99-
1.04). Relative to women who never used estrogen and progesterone, women who used 
for 5-10 years had 1.75 times the risk of breast cancer (95% CI 1.01-3.01) and women 
who used for 10 or more years had 1.05 times the risk of breast cancer (0.54-2.05).  
Women who received a needle aspiration of the breast had 1.30 times the risk of breast 
cancer relative to women who had never received a needle aspiration (95% CI 0.87-1.95).  
Women who had a bilateral oophorectomy or a hysterectomy had a 46% (95% CI -.34-
0.85) and 33% (95% CI 0.50-0.94) reduction in breast cancer risk, respectively. Women 
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with a family history of breast cancer had 1.85 times the risk of breast cancer relative to 
women with no family history (95% CI 1.67-2.92). Women who were past or current 
smokers had 1.08 (95% CI 0.80-1.46) and 1.32 (95% CI 0.72-2.40) times the risk of 
breast cancer relative to women who never smoked. Quality of sleep and hours of sleep 
were not significantly associated with breast cancer risk. Compared to those who only 
completed high school, those who completed a graduate education had 2.2 times the risk 
of breast cancer (95% CI 1.47-3.28).  
 Median levels of creatinine adjusted melatonin by breast cancer risk factors are 
presented in Table 2. Creatinine adjusted melatonin levels decreased as body mass index 
increased. Those who completed higher levels of education had higher levels of 
creatinine adjusted melatonin. There was a general decrease in creatinine adjusted 
melatonin as age increased. Women who had given birth to more children had higher 
levels of creatinine adjusted melatonin, as compared to women who had not given birth. 
Higher levels of quality of sleep and duration of sleep both led to higher levels of 
creatinine adjusted melatonin, though levels were fairly similar for those who slept 7, 8 or 
9 hours. Never smokers appear to have lower levels of creatinine adjusted melatonin 
compared to past and current smokers, who have similar levels.  
 The initial multiple predictor conditional logistic regression model of breast 
cancer and creatinine adjusted melatonin (coded as quartiles) included matching factors 
plus the following confounders: age of menopause, needle aspiration of the breast, 
duration of estrogen and progesterone therapy, years since quitting hormone replacement 
therapy, body mass index, ethnicity, energy expenditure from physical activity and 
highest education level. Each covariate was taken out of the model one at a time and a 
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likelihood ratio test was conducted to see if the covariate was statistically significant. 
Any covariate with a p-value less than 0.05 were included in the final model.  Age of 
menopause, needle aspiration, duration of estrogen and progesterone therapy, years since 
quitting hormone replacement therapy, ethnicity and energy expenditure from physical 
activity had p-values greater than 0.05, and were dropped from the model, leaving highest 
education level and body mass index. The odds ratio and 95% CI for the model adjusted 
for body mass index and education level are presented in Table 3 as the multivariable 
model. In the fully adjusted model, relative to the lowest quartile of creatinine adjusted 
melatonin, the risk of breast cancer was 0.85 (95% CI 0.52-1.37), 1.05 (95% CI 0.65-
1.72), and 1.09 (95% CI 0.66-1.81) for women in the second, third and fourth quartile, 
respectively. In the model adjusted for body mass index and education level, relative to 
the lowest quartile of creatinine adjusted melatonin, the risk of breast cancer was 0.98 
(95% CI 0.63-1.54), 1.26 (95% CI 0.80-1.97), and 1.20 (95% CI 0.76-1.90) for women in 
the second, third and fourth quartile, respectively.  When analysis was run with creatinine 
adjusted melatonin as a continuous variable the results did not change (OR=1.00, 95% CI 
0.99-1.01). After adjusting the continuous creatinine adjusted melatonin for known breast 
cancer risk factors the results did not change (OR=1.01, 95% CI 0.99-1.02). 
 In ancillary analysis, we explored whether there was an association between sleep 
duration and breast cancer risk (Table 4). From the fully adjusted model, adjusting for 
age of menopause, needle aspiration, duration of estrogen and progesterone therapy, 
years since quitting hormone replacement therapy, ethnicity and energy expenditure from 
physical activity, we found that compared to women who slept 5 hours or less, the risk of 
breast cancer was 0.87 (95% CI 0.43-1.75), 1.05 (95 % CI 0.53-2.11), 0.92 (95% CI 0.43-
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1.97) and 0.71 (95% CI 0.26-1.92) for those who slept 6 hours, 7 hours, 8 hours and 9+ 
hours, respectively. The results did not significantly change was adjusting for creatinine 
adjusted melatonin.  
 We assessed differences in results by tumor receptor status and smoking status. 
The odds ratios for the analysis restricted to those who were ER+ and stratified on 
smoking status are presented in Table 5. Among the women with ER+ receptor status 
(n=176), relative to the lowest quartile, the risk of breast cancer was 0.69 (95% CI 0.39-
1.23), 0.72 (95% CI 0.40-1.29) and 0.83 (95% CI 0.46-1.51) for the women in the 
second, third and fourth quartile, respectively.  There were too few women who had ER- 
receptor status to complete an analysis (n=36). The remaining women had borderline 
(n=1), unavailable (n=9) or unknown receptor status (n=17).  
 When current smokers were excluded, the risk of breast cancer relative to women 
in the lowest quartile of creatinine adjusted melatonin is 1.01 (95% CI 0.60-1.70), 1.19 
(95% CI 0.70-2.02) and 1.41 (95% CI 0.81-2.44) for women in the second, third and 
fourth quartile respectively. There were too few current smokers to analyze the 
association of melatonin and breast cancer in this subgroup (20 cases and 31 controls). 
 In another ancillary analysis, we considered the subgroup of women diagnosed 
within 4 years of urine collection, women diagnosed between 4 to 7 years after urine 
collection and those diagnosed 7 or more years after urine collection. The results of these 
analyses are presented in Table 6. In every subgroup we found no association between 
creatinine adjusted melatonin and breast cancer risk. For those diagnosed within 4 years, 
relative to women in the first quartile of creatinine adjusted melatonin, the odds ratios are 
0.86 (95% CI 0.32-2.30), 1.42 (95% CI 0.54-3.75) and 1.40 (95% CI 0.51-3.81) for 
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women in the second, third and fourth quartile respectively. For those diagnosed between 
4-7 years after diagnosis, relative to women in the first quartile of creatinine adjusted 
melatonin, the odds ratios are 0.52 (95% CI 0.18-1.52), 1.79 (95% CI 0.67-4.76) and 1.26 
(95% CI 0.49-3.12) for women in the second, third and fourth quartile respectively. For 
those women diagnosed 7 or more years are urine collection, relative to women in the 
first quartile of creatinine adjusted melatonin, the odds ratios are 0.85 (95% CI 0.85-
1.94), 0.81 (95% CI 0.33-1.95) and 0.94 (95% CI 0.42-2.13) for women in the second, 
third and fourth quartile respectively. 
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CHAPTER V 
DISCUSSION 
 Contrary to our hypothesis, this study did not find a statistically significant 
relationship between urinary melatonin and breast cancer risk.  The aim of this study was 
to examine the relationship between creatinine adjusted urinary melatonin levels and 
invasive breast cancer risk in postmenopausal women. The Women’s Health Initiative 
Observational Study presented an opportunity to use a large prospective cohort with a 
long follow-up and first morning urine sample. Several studies have looked at urinary 
melatonin and breast cancer risk, but results have been conflicting.7-12  
 The mean creatinine adjusted melatonin found in our study, 16.29 ng/mg for cases 
and 16.05 ng/mg for controls, was different than what has been seen in previous studies. 
The means found within our study were higher compared to Travis et al., who found 
means of 6.47 ng/mg for cases and 6.57 ng/mg for controls.12  The tertile cutoff points 
were also lower than our quartile cutoff points.  The study conducted within the Nurses 
Health II also found lower mean creatinine adjusted melatonin levels, 10.8 ng/mg for 
cases and 12.7 ng/mg for controls.11 The quartile cutoff points used were similar, but 
slightly higher for this study. The final three prospective studies conducted to date had 
higher mean creatinine adjusted melatonin levels, 29.3 ng/mg for cases and 27.6 ng/mg 
for controls8, 21.0 ng/mg for cases and 23.5 ng/mg for controls9, 24.5 ng/ng for cases and 
28.8 ng/mg for controls.10 Two of these studies did not use creatinine adjusted melatonin 
to create the quartiles8,9. The one study that did use creatinine adjusted melatonin 
quartiles had higher quartile cutoff points than our study.10  
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 Of the five prospective studies conducted to date, one examined premenopausal 
women8, two examined both pre- and postmenopausal women11,12 and two examined only 
postmenopausal women.9,10 A nested case-control conducted within the Nurses Health 
Study II among mostly premenopausal women found an inverse association between 
melatonin and breast cancer risk, the risk for invasive breast cancer for the highest 
quartile of creatinine adjusted melatonin compared to the lowest was 0.59 (95% CI 0.34-
1.00).11 This association was slightly weakened when those women with in situ breast 
cancer were included (OR=0.68, 95% CI 0.44-1.06).  In comparison, the study conducted 
in the ORDET cohort among premenopausal women found a risk of 1.43 (95% CI 0.83-
2.45) for all breast cancers comparing the fourth quartile of melatonin to the first.8 A 
statistically significant inverse association was found in only one subgroup analysis, that 
of women who were diagnosed 8 years after urine collection. In the study conducted 
within the Guernsey cohort, no association was found between urinary melatonin levels 
and breast cancer risk in either pre or postmenopausal women.12 The authors used a 24-
hour collection of urine, which would not accurately measure the peak melatonin 
production, which was stated as a possible reason for the lack of association.9,10,12 We 
used a first morning sample and were able to capture the peak melatonin level, so this is 
not a limitation for our study. The study conducted within the Nurses Health Study found 
an inverse association between creatinine adjusted melatonin and breast cancer risk 
(OR=0.62, 95% CI 0.41-0.95 for the fourth quartile compared to the first).10 This 
association was weakened when in situ cancers were removed (OR=0.74, 95% CI 0.46-
1.21 for the fourth quartile compared to the first), as compared to the Nurses Health II, 
which found less of an association with in situ breast cancer among premenopausal 
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women.8  The ORDET cohort investigators found an inverse relationship between 
melatonin and breast cancer risk (OR=0.65, 95% CI 0.39-1.09 for the fourth quartile 
relative to the first quartile).9 The association increased when current smokers were 
excluded from the analysis (OR=0.38, 95% CI 0.20-0.74).  
 The cases in our study were all diagnosed with invasive breast cancer, so we were 
unable to assess variations in the association between in situ and invasive breast cancer as 
seen in previous studies.10-12 When we excluded current smokers the risk of breast cancer 
appears to have increased, but this was non-significant. Previous studies that restricted to 
ER+ receptor status saw no change in risk.9,10 We saw an inverse relationship between 
creatinine adjusted melatonin and breast cancer risk when we restricted to ER+ receptor 
status, but this was non-significant. Unlike the study that found a significant inverse 
association when analysis was restricted to women diagnosed 8 years after urine 
collection8, we found no difference when we limited the analysis to those women who 
were diagnosed 7 years after urine collection.  
 One possible limitation of our study is nondifferential misclassification of 
exposure. The first morning urine samples were assayed for melatonin levels using the 
ELISA method, a validated method.6 If melatonin levels were incorrectly measured, this 
misclassification would attenuate the results seen in this study. This is unlikely to occur, 
as the ELISA assay is a validated assay. Additionally, the lab personnel were blinded to 
the case status of the urine samples. It is possible that the urine samples were incorrectly 
collected or stored. This would also attenuate the results seen. Urinary melatonin levels 
have been found to be stable over time, allowing for one sample to be a representative 
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sample over many years, so the sample collected at baseline should be an accurate 
representation of melatonin exposure over time.8   
 Within the context of a nested case-control study, selection bias will occur if 
participants differentially drop out of the study based upon exposure and disease status. If 
a differential loss to follow-up occurred this could cause either an increase or decrease of 
the association seen. This is unlikely in our study, as all the women were followed very 
closely for many years and any women who did not complete a questionnaire was cross-
referenced against breast cancer registries and the National Death Index to see if they had 
died or gone on to develop a disease. Additionally, the completion rates of the annual 
questionnaires were between 93-96%, indicating that there was a high degree of follow-
up.20  
 The Women’s Health Initiative is a large prospective cohort, which allowed for 
the collection of many potential confounding factors. Using information gathered from 
the baseline questionnaire, as well as the subsequent questionnaires, we were able to 
evaluate and control for many potential confounding factors.  We assessed known breast 
cancer risk factors as identified from other WHI studies, as well as other factors 
considered in independent studies assessing urinary melatonin and breast cancer risk. 
While we were able to address many known confounders, it is possible that we have 
missed other lesser-known factors.  
 The results of this study is plausibly generalizable to all women at risk for 
postmenopausal breast cancer, as there is no reason to believe that the biological 
mechanism through which melatonin affects breast cancer risk varies. It is possible that 
menopausal status could alter the relationship between melatonin and breast cancer, as 
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pre- and postmenopausal breast cancers have different physiological mechanisms. Thus, 
more research will have to be conducted to see if the relationship between melatonin 
levels and pre- and postmenopausal breast cancer risk differ.  
 In summary, our study found no association between creatinine adjusted 
melatonin levels and invasive postmenopausal breast cancer risk. Relatively few studies 
have assessed the relationship between melatonin and risk of postmenopausal breast 
cancer and have provided inconsistent results.7-12 Using a sample from the large Women’s 
Health Initiative Observational Study cohort allowed for a large number of women to be 
assessed for a long period of follow-up. Additionally, the urine sample was collected as a 
first morning urine sample, believed to be a more reliable estimate than the 24-hour 
sample method. Analysis accounting for lag time, smoking status and ER+ receptor status 
did not significantly alter our findings. Additional studies will be needed that allow for 
long periods of follow-up, a large study population and first morning urine samples to 
confirm our results.  
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APPENDIX A 
HUMAN SUBJECT PROTECTION 
 All subjects recruited to the Women’s Health Initiative signed an informed 
consent agreement understanding that they would participate in a longitudinal cohort 
study. Consenters also understood that they could discontinue their participation at any 
time. To protect confidentiality, all identifying factors were removed from the data set 
prior to our receipt. In our dataset, all participants are only identified by a study ID.  
 There were no known risks to participation in this study. The only potential 
concern is privacy and confidentiality, but we analyzed de-identified data and it was 
stored on a secure file. There were no known benefits for the study participants, other 
than contributing pertinent scientific data for this and other studies.  
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APPENDIX B 
PERMISSION TO ACCESS DATA 
 I received permission to use Women’s Health Initiative Observational Study data 
to assess the relationship between melatonin levels and risk of postmenopausal breast 
cancer.  
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APPENDIX C 
TABLES 
 
Table 1. Baseline characteristics of postmenopausal breast cancer cases and matched controls (N=773) 
Covariate Cases (n=258) Controls (n=515) p-valuea OR 95% CI 
Creatinine adjusted 
melatonin level mean 
(sd) 
16.29 ng/mg 
(11.9) 
16.05 ng/mg 
(12.9) 
0.801   
      
Age stratum at 
enrollment n (%)  
     
     50-54 32 (12.40%) 70 (13.59%) 0.805 1.0 (referent)  
     55-59 48 (18.60%) 89 (17.28%)  2.0 0.59-6.74 
     60-69 119 (46.12%) 250 (48.54%)  1.84 0.39-8.78 
     70-79 59 (22.87%) 106 (20.58%)  4.4 0.68-28.23 
      
Ethnicity n (%)      
    White 211 (81.78%) 418 (81.17%) 0.874 1.0 (referent)  
    Black 31 (12.02%) 60 (11.65%)   1.02 0.61-1.72 
    Other race 16 (6.2%) 37 (7.18%)   0.77 0.35-1.70 
         
Highest education level 
n (%) 
        
      High school or less 88 (34.11%) 220 (43.72%) 0.001 1.0 (referent)  
      College 81 (31.40%) 182 (35.34%)   1.13 0.78-1.64 
      Post graduate 86 (33.33%) 108 (20.97%)   2.20 1.47-3.28 
          
Number of live births n 
(%) 
        
    Never pregnant 31 (12.02%) 54 (10.49%) 0.068 1.0 (referent)  
    Never had term 
pregnancy 
7 (2.71%) 3 (0.58%)   5.7 1.10-29.58 
   1 23 (8.91%) 56 (10.87%)   0.72 0.38-1.39 
   2-4 148 (57.36%) 321 (62.33%)   0.83 0.52-1.33 
   5+ 47 (18.22%) 78 (15.15%)   1.14 0.65-2.01 
          
BMI categories n (%)         
    <24.9 90 (34.88%) 203 (39.42%) 0.455 1.12 0.96-1.30 
      25-29.9 85 (32.95%) 171 (33.20%)     
      30-34.9 45 (17.44%) 81 (15.73%)     
      35+ 36 (13.95%) 56 (10.87%)     
      
Quality of sleep n (%)        
       Restless 36 (13.95%) 65 (12.62%) 0.211 1.0 (referent)  
       Average quality 121 (46.90%) 212 (41.17%)  1.04 0.65-1.68 
       Restful 100 (38.76%) 232 (45.05%)   0.78 0.49-1.25 
Notes: a. P-value for t-tests or chi-squared tests, as appropriate 
Abbreviations: OR- Odds Ratio, sd- Standard Deviation, se- standard error, BMI- Body Mass Index, HRT-
Hormone replacement therapy 
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Table 2.  Median creatinine adjusted melatonin levels by baseline characteristics in 515 controls  
Covariates Median Creatinine Adjusted Melatonin (ng/mg)  P-valuea 
Age stratum at enrollment   
     50-54 (n=70) 11.00  0.03 
     55-59 (n=89) 17.60  
     60-69 (n=250) 13.24   
     70-79 (n=106) 10.79   
   
Ethnicity    
    White (n=418) 14.42  0.05 
    Black (n=60)   9.48   
    Other (n=37) 10.45   
   
Highest education level    
      High school or less (n=220) 11.60  0.06 
      College (n=182) 14.52   
      Post graduate (n=108) 
      Missing (n=5) 
14.81   
    
Number of live births   
    Never pregnant (n=54) 13.24 0.38 
    Never had term pregnancy (n=3)   6.69  
   1 (n=56) 10.75  
   2-4 (n=321) 13.90  
   5+ (n=78) 
   Missing (n=3) 
15.39  
    
BMI categories    
    <24.9 (n=203) 14.57  0.0068 
      25-29.9 (n=171) 14.07   
      30-34.9 (n=81) 12.09   
      35+ (n=56) 
      Missing (n=4) 
  9.70   
   
Quality of sleep    
       Restless (n=65) 11.30  0.33 
       Average quality (n=212) 12.42   
       Restful (n=232) 
      Missing (n=6) 
14.64   
   
Hours of sleep    
      5 or less hours (n=36) 10.20  0.48 
      6 hours (n=134) 11.23   
      7 hours (n=209) 14.40   
      8 hours (n=104) 15.47   
      9 or more hours (n=28) 
      Missing (n=4) 
14.92   
Notes: a. P-value from Kruskal-Wallis test 
Abbreviations: OR- Odds Ratio, BMI- Body Mass Index, HRT-Hormone replacement therapy 
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Table 3. Odds ratios (OR) and 95% confidence intervals of breast cancer by quartile 
of creatinine adjusted melatonin  
 Number 
of cases 
/controls 
Unadjusted OR 
(95% CI) 
Fully Adjusteda OR 
(95% CI) 
 
Multivariableb OR 
(95% CI) 
Quartile 1 58/127 1.00 (Referent) 1.00 (Referent) 1.00 (Referent) 
Quartile 2 60/130 1.02 (0.66-1.56) 0.85 (0.52-1.37) 0.98 (0.63-1.54) 
Quartile 3 60/130 1.26 (0.82-1.94) 1.05 (0.65-1.72) 1.26 (0.80-1.97) 
Quartile 4 74/129 1.13 (0.73-1.75) 1.09 (0.66-1.81) 1.20 (0.76-1.90) 
Notes: a. Adjusted for body mass index, education level, age of menopause, needle aspiration, energy 
expenditure from recreational activity, years since quitting hormone replacement therapy, duration of estrogen 
and progesterone use and ethnicity 
         b. Adjusted for body mass index and education level 
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Table 4. Odds ratios (OR) and 95% confidence intervals of breast cancer by sleep duration  
 Number 
of cases/ 
controls 
Unadjusted OR  
(95% CI) 
Fully Adjusted ORa 
(95% CI) 
 
Fully Adjusted and 
Creatinine Adjusted 
Melatonin Levelsb 
OR (95% CI) 
5 hours 
or less 
19/36 1.00 (referent) 1.00 (referent) 1.00 (referent) 
6 hours 68/134 0.94 (0.50-1.79) 0.87 (0.43-1.75) 0.87 (0.43-1.77) 
7 hours 107/209 0.96 (0.51-1.80) 1.05 (0.53-2.11) 1.06 (0.53-2.15) 
8 hours 49/104 0.88 (0.45-1.73) 0.92 (0.43-1.97) 0.89 (0.41-1.92) 
9+ 
hours 
14/28 0.92 (0.38-2.21) 0.71 (0.26-1.92) 0.84 (0.51-1.38) 
Notes: a. Adjusted for body mass index, education level, age of menopause, needle 
aspiration, energy expenditure from recreational activity, years since quitting hormone 
replacement therapy, duration of estrogen and progesterone use and ethnicity 
           b. Adjusted for creatinine adjusted melatonin level, body mass index, education level, 
age of menopause, needle aspiration, energy expenditure from recreational activity, years 
since quitting hormone replacement therapy, duration of estrogen and progesterone use and 
ethnicity 
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Table 5. Odds ratios (OR) and 95% confidence interval of breast cancer by 
smoking status and ER+ receptor status  
 Number of 
cases/controls 
Removed current 
smokersa 
Number of 
cases/controls 
 
ER+a 
 
Quartile 1 50/116 1.0 referent 52/96 1.0 referent 
Quartile 2 57/124 1.01 (0.60-1.70) 42/98 0.69 (0.39-1.23) 
Quartile 3 70/121 1.19 (0.70-2.02) 52/96 0.72 (0.40-1.29) 
Quartile 4 60/116 1.41 (0.81-2.44) 49/99 0.83 (0.46-1.51) 
Notes: a. Adjusted for body mass index, education level, age of menopause, needle aspiration, energy 
expenditure from recreational activity, years since quitting hormone replacement therapy, duration of 
estrogen and progesterone use and ethnicity 
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Table 6.  Odds ratios (OR) and 95% confidence intervals of breast cancer and creatinine 
adjusted melatonin by year of diagnosis  
 Number of 
cases/ 
controls 
Less than 4 
yearsa 
Number 
of cases/ 
controls 
4-7 yearsa Number of 
cases/ 
controls 
7 or more 
yearsa 
Quartile 
1 
15/40 1.00 
(Referent) 
20/39 1.00 
(Referent) 
20/39 1.00 
(Referent) 
Quartile 
2 
17/40 0.86  
(0.32-2.30) 
 17/40 0.52  
(0.18-1.52) 
20/40 0.85  
(0.37-1.94) 
Quartile 
3 
26/40 1.42  
(0.54-3.75) 
 24/39 1.79  
(0.67-4.76) 
20/40 0.81  
(0.33-1.95) 
Quartile 
4 
22/40 1.40  
(0.51-3.81) 
 18/40 1.26 
(0.49-3.12) 
20/40 0.94 
(0.42-2.13) 
Notes: a. Adjusted for body mass index, age of menopause, needle aspiration, energy expenditure 
from recreational activity, years since quitting hormone replacement therapy, duration of estrogen 
and progesterone use and ethnicity 
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